Osimertinib
VIDEO: Expert offers advice for residents seeing patients with EGFR-mutated lung cancer
In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, offers advice to new residents seeing patients with EGFR-mutated lung cancer.
VIDEO: ‘Flurry of activity’ in treatment space for EGFR-mutated lung cancer
In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, discusses the changing treatment landscape in EGFR-mutated lung cancer.
Lung Cancer Awareness Month: Potential new standard in NSCLC, immunotherapy timing matters
Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.
Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of October 14, 2024
In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more.
FDA expands osimertinib approval for advanced non-small cell lung cancer
The FDA approved osimertinib for treatment of certain patients with locally advanced or unresectable non-small cell lung cancer.
FDA approves first-line combination for EGFR-mutant non-small cell lung cancer
The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.
World Lung Cancer Day: Risks of vaping; an ‘unprecedented’ advance in ALK-positive disease
Today is World Lung Cancer Day.
Lung Cancer: Assessment and Treatment
‘Broader and more inclusive design’ needed for novel cancer trials
Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.
Lung cancer dominates ASCO social media conversation among health care professionals
Discussion about lung cancer research breakthroughs dominated the social media conversation among health care professionals during this year’s ASCO Annual Meeting.